GPCR
Structure Therapeutics Inc.Healthcare · $2.4B market cap
Verdict
We can't put a fair value on GPCR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow GPCR
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 3 sales and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Lin Xichen
CHIEF SCIENTIFIC OFFICER · 2026-09-01
Sold
100 shares
Lin Xichen
CHIEF SCIENTIFIC OFFICER · 2026-09-01
Sold
4,539 shares
Lin Xichen
CHIEF SCIENTIFIC OFFICER · 2026-09-01
Sold
1,300 shares
Other filings
About Structure Therapeutics Inc.
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works